Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Reviews in Clinical and Experimental Pharmacology
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 2772-4328
  • E-ISSN: 2772-4336

Abstract

Background

Pancreatic Cancer (PC) is one of the most malignant tumors and highly invasive neoplasms around the world.

Objective

This systematic review and meta-analysis aims to study the relationship between the use of renin-angiotensin-aldosterone system inhibitors and the incidence and mortality of PC.

Methods

The electronic search was conducted systematically until October 10, 2023. in databases, including Scopus, Web of Science (WOS), PubMed/MEDLINE, Cochrane Library, and Embase. The required data were extracted from the articles and were analyzed by Stata 15 using statistical tests (Chi-square and I2), Forest plots, and publication bias tests (Begg's and Egger's tests).

Results

A total of four studies (2011-2019; n=314,856) investigated the relationship between RAS antagonists and PC risk. No significant associations were found between angiotensin receptor blockers (ARBs) (OR=0.94, 95% CI: 0.77-1.14, =0.513), angiotensin-converting enzyme inhibitors (ACEIs) (OR=0.96, 95% CI: 0.84-1.09, =0.505), or combination therapy (ARBs + ACEIs) (OR=0.97, 95% CI: 0.87-1.09, =0.627) and PC risk. Also, nine studies (2010-2023; n=20,483) examined the association between renin-angiotensin-aldosterone system inhibitors and PC mortality. Significant reductions in PC mortality were found for ARBs (OR=0.81, 95% CI: 0.66-0.98, =0.032), ACEIs (OR=0.89, 95% CI: 0.80-0.99, =0.038), and combination therapy (OR=0.83, 95% CI: 0.70-0.97, =0.022). No evidence of publication bias was found in the study results.

Conclusion

In summary, while renin-angiotensin-aldosterone system inhibitors did not appear to impact PC risk, their use was associated with lower PC mortality based on this meta-analysis of the current evidence. More rigorous and well-designed studies are required to validate and support these findings.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crcep/10.2174/0127724328291047240409062436
2024-04-16
2025-01-07

  • From This Site

    /content/journals/crcep/10.2174/0127724328291047240409062436
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BrayF. FerlayJ. SoerjomataramI. SiegelR.L. TorreL.A. JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.201868639442410.3322/caac.21492 30207593
     [Google Scholar]
  2. RawlaP. SunkaraT. GaduputiV. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors.World J. Oncol.2019101102710.14740/wjon1166 30834048
     [Google Scholar]
  3. ZhaoZ. LiuW. Pancreatic cancer: A review of risk factors, diagnosis, and treatment.Technol. Cancer Res. Treat.20201910.1177/1533033820962117 33357065
     [Google Scholar]
  4. HenryA.C. van DongenJ.C. van GoorI.W.J.M. Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: Nationwide, observational cohort study.BJS Open202372zrac17410.1093/bjsopen/zrac174 36959099
     [Google Scholar]
  5. WeiJ. ZhouZ. XuZ. Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension.PeerJ20197e818810.7717/peerj.8188 31844581
     [Google Scholar]
  6. Malangone-MonacoE. DolehY. ColeA. NoxonV. AnticoG. PishvaianM.J. The economic burden of metastatic pancreatic cancer.Pancreatology20202071434144110.1016/j.pan.2020.09.002 32967794
     [Google Scholar]
  7. CiporaE. PartykaO. PajewskaM. Treatment costs and social burden of pancreatic cancer.Cancers2023156191110.3390/cancers15061911 36980796
     [Google Scholar]
  8. MiyakiC. LynchL.M. An update on common pharmaceuticals in the prevention of pancreatic cancer.Cureus2022145e2549610.7759/cureus.25496 35800820
     [Google Scholar]
  9. JiangW. HeR. LuY. ZhouW. The relationships between antihypertensive medications and the overall survival of patients with pancreatic cancer: A systematic review and meta-analysis.Expert Rev. Gastroenterol. Hepatol.202216654755310.1080/17474124.2022.2088506 35686669
     [Google Scholar]
  10. ShinK. YangJ. YuY. SonE. KimK. KimY.H. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: An updated meta-analysis of observational studies.Ther. Adv. Drug Saf.20221310.1177/20420986221129335 36249084
     [Google Scholar]
  11. LiE.C.K. HeranB.S. WrightJ.M. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.Cochrane Libr.201420148CD00909610.1002/14651858.CD009096.pub2 25148386
     [Google Scholar]
  12. HerA.Y. ChoiB.G. RhaS.W. KimY.H. ChoiC.U. JeongM.H. The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension.PLoS One20201511e024231410.1371/journal.pone.0242314 33253206
     [Google Scholar]
  13. TurnerJ.M. KodaliR. Should angiotensin-converting enzyme inhibitors ever be used for the management of hypertension?Curr. Cardiol. Rep.20202299510.1007/s11886‑020‑01352‑8 32648000
     [Google Scholar]
  14. TimmermansP.B. WongP.C. ChiuA.T. Angiotensin II receptors and angiotensin II receptor antagonists.Pharmacol. Rev.1993452205251 8372104
     [Google Scholar]
  15. PoredosP. JezovnikM.K. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis.Int. Angiol.2007264306311 18091697
     [Google Scholar]
  16. RachowT. SchifflH. LangS.M. Risk of lung cancer and renin–angiotensin blockade: A concise review.J. Cancer Res. Clin. Oncol.2021147119520410.1007/s00432‑020‑03445‑x 33231730
     [Google Scholar]
  17. JungM.H. LeeJ.H. LeeC.J. Effect of angiotensin receptor blockers on the development of cancer: A nationwide cohort study in korea.J. Clin. Hypertens.202123487988710.1111/jch.14187 33492766
     [Google Scholar]
  18. LeeS.H. ParkJ. ParkR.W. Renin-angiotensin-aldosterone system inhibitors and risk of cancer: A population-based cohort study using a common data model.Diagnostics 202212226310.3390/diagnostics12020263 35204354
     [Google Scholar]
  19. SobczukP. SzczylikC. PortaC. CzarneckaA. Renin angiotensin system deregulation as renal cancer risk factor (Review).Oncol. Lett.20171455059506810.3892/ol.2017.6826 29098020
     [Google Scholar]
  20. BraskyT.M. FloresK.F. LarsonJ.C. Associations of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with colorectal cancer risk in the women’s health initiative.Cancer Epidemiol. Biomarkers Prev.20213051029103210.1158/1055‑9965.EPI‑20‑1401 33627382
     [Google Scholar]
  21. PetersonJ. WelchV. LososM. TugwellP. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.OttawaOttawa Hospital Research Institute2011112
     [Google Scholar]
  22. KhuranaV. CalditoG. BarkinJ.S. Angiotensin converting enzyme inhibitors decrease the incidence of pancreatic cancer: A study of half a million US veterans.Eur. J. Cancer, Suppl.200641474810.1016/S1359‑6349(06)80521‑5
     [Google Scholar]
  23. FujimotoM. KanouM. HosomiK. TakadaM. Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database.Int. J. Clin. Pharmacol. Ther.201755429530310.5414/CP202842 28079518
     [Google Scholar]
  24. TseG. ZhouJ. LeeS. Incidence of pancreatic cancer in angiotensin-converting enzyme inhibitors (ACEIs) versus angiotensin receptor blockers (ARBs): A population-based cohort study.medRxiv20222022.200710.1101/2022.07.26.22278092
     [Google Scholar]
  25. ChinH.J. OhS.W. GooH.S. Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis.J. Korean Med. Sci.2011261596610.3346/jkms.2011.26.1.59 21218031
     [Google Scholar]
  26. MandilarasV. BouganimN. YinH. AsselahJ. AzoulayL. The use of drugs acting on the renin–angiotensin system and the incidence of pancreatic cancer.Br. J. Cancer2017116110310810.1038/bjc.2016.375 27846200
     [Google Scholar]
  27. WangZ. WhiteD. HoogeveenR. anti-hypertensive medication use, soluble receptor for glycation end products and risk of pancreatic cancer in the women’s health initiative study.J. Clin. Med.20187819710.3390/jcm7080197 30072610
     [Google Scholar]
  28. KirkegårdJ. MortensenF.V. Cronin-FentonD. Antihypertensive drugs and pancreatic cancer risk in patients with chronic pancreatitis: A Danish nationwide population-based cohort study.Br. J. Cancer2019121762262410.1038/s41416‑019‑0562‑y 31474760
     [Google Scholar]
  29. NakaiY. IsayamaH. IjichiH. Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.Br. J. Cancer2010103111644164810.1038/sj.bjc.6605955 20978506
     [Google Scholar]
  30. NakaiY. IsayamaH. SasakiT. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: Better prognosis with statin use in diabetic patients.Pancreas201342220220810.1097/MPA.0b013e31825de678 23000889
     [Google Scholar]
  31. TingleS.J. MoirJ.A. WhiteS.A. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.World J. Gastrointest. Pathophysiol.20156423524210.4291/wjgp.v6.i4.235 26600982
     [Google Scholar]
  32. CerulloM. GaniF. ChenS.Y. CannerJ.K. PawlikT.M. Impact of angiotensin receptor blocker use on overall survival among patients undergoing resection for pancreatic cancer.World J. Surg.20174192361237010.1007/s00268‑017‑4021‑8 28429090
     [Google Scholar]
  33. BagniK. ChenI.M. JohansenA.Z. Prognostic impact of charlson’s age‐comorbidity index and other risk factors in patients with pancreatic cancer.Eur. J. Cancer Care2020293e1321910.1111/ecc.13219 31908093
     [Google Scholar]
  34. StøerN.C. BoucheG. PantziarkaP. SloanE.K. AndreassenB.K. BotteriE. Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: A nationwide registry-based study in Norway.Acta Oncol.20216091146115310.1080/0284186X.2021.1953136 34338111
     [Google Scholar]
  35. KeithS.W. MaioV. ArafatH.A. Angiotensin blockade therapy and survival in pancreatic cancer: A population study.BMC Cancer202222115010.1186/s12885‑022‑09200‑4 35130875
     [Google Scholar]
  36. HüttnerF.J. MauchM. HecklerM. Influence of beta-blockers and other non-cancer drugs on outcomes after pancreatic cancer resection.Br. J. Surg.2023110449849910.1093/bjs/znac434 36726045
     [Google Scholar]
  37. YoonC. YangH.S. JeonI. ChangY. ParkS.M. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: A meta-analysis of observational studies.CMAJ201118314E1073E108410.1503/cmaj.101497 21876027
     [Google Scholar]
  38. SipahiI. ChouJ. MishraP. DebanneS.M. SimonD.I. FangJ.C. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk.Am. J. Cardiol.2011108229430110.1016/j.amjcard.2011.03.038 21600543
     [Google Scholar]
  39. YaoM. MaJ. WuD. Neutrophil extracellular traps mediate deep vein thrombosis: from mechanism to therapy.Front. Immunol.202314119895210.3389/fimmu.2023.1198952 37680629
     [Google Scholar]
  40. MaoY. XuX. WangX. ZhengX. XieL. Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?Oncotarget2016766765677310.18632/oncotarget.6837 26760503
     [Google Scholar]
  41. Mc MenaminÚ.C. MurrayL.J. CantwellM.M. HughesC.M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: A systematic review.Canc Cau Cont201223222123010.1007/s10552‑011‑9881‑x 22116540
     [Google Scholar]
  42. SongT. ChoiC.H. KimM.K. KimM.L. YunB.S. SeongS.J. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis.Eur. J. Cancer Prev.2017261788510.1097/CEJ.0000000000000269 27158979
     [Google Scholar]
  43. McGuiganA. KellyP. TurkingtonR.C. JonesC. ColemanH.G. McCainR.S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.World J. Gastroenterol.201824434846486110.3748/wjg.v24.i43.4846 30487695
     [Google Scholar]
  44. ShenJ. HuangY.M. WangM. Renin–angiotensin system blockade for the risk of cancer and death.J Renin Angiot Aldost Syst201617310.1177/1470320316656679 27402638
     [Google Scholar]
  45. NguyenN.T.H. NguyenP.A. HuangC.W. Renin-angiotensin-aldosterone system inhibitors and development of gynecologic cancers: A 23 million individual population-based study.Int. J. Mol. Sci.2023244381410.3390/ijms24043814 36835224
     [Google Scholar]
  46. SunH. LiT. ZhuangR. CaiW. ZhengY. Do renin–angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?Medicine20179613e639410.1097/MD.0000000000006394 28353566
     [Google Scholar]
  47. AlmutlaqM. AlamroA.A. AlamriH.S. AlghamdiA.A. BarhoumiT. The effect of local renin angiotensin system in the common types of cancer.Front. Endocrinol.20211273636110.3389/fendo.2021.736361 34539580
     [Google Scholar]
  48. PinterM. JainR.K. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Sci. Transl. Med.20179410eaan561610.1126/scitranslmed.aan5616 28978752
     [Google Scholar]
  49. YangJ. YangX. GaoL. ZhangJ. YiC. HuangY. The role of the renin-angiotensin system inhibitors in malignancy: A review.Am. J. Cancer Res.2021113884897 33791161
     [Google Scholar]
  50. PinterM. KwantenW.J. JainR.K. Renin–angiotensin system inhibitors to mitigate cancer treatment–related adverse events.Clin. Cancer Res.201824163803381210.1158/1078‑0432.CCR‑18‑0236 29610292
     [Google Scholar]
  51. MakarG.A. HolmesJ.H. YangY.X. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk.J. Natl. Cancer Inst.20141062djt37410.1093/jnci/djt374 24431411
     [Google Scholar]
/content/journals/crcep/10.2174/0127724328291047240409062436
Loading
The Association between use of Renin-Angiotensin-Aldosterone System Inhibitors and the Risk and Mortality of Pancreatic Cancer: A Systematic Review and Meta-Analysis
Curr Rev Clin Exper Pharm 20, 60 (2025); https://doi.org/10.2174/0127724328291047240409062436
/content/journals/crcep/10.2174/0127724328291047240409062436
/content/journals/crcep/10.2174/0127724328291047240409062436
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; invasive neoplasms; Pancreatic cancer; renin-angiotensin system; renin-angiotensin-aldosterone

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test